Raw Cameron, Traub Rebecca J, Wiethoelter Anke
Melbourne Veterinary School, Faculty of Science, University of Melbourne, Parkville, VIC, Australia.
Front Vet Sci. 2024 Sep 5;11:1460452. doi: 10.3389/fvets.2024.1460452. eCollection 2024.
Tropical climates in remote Aboriginal and Torres Strait Islander communities in northern Australia are conducive to the transmission of canine helminths such as hookworms, as well as ectoparasites such as fleas and ticks. In addition to their veterinary importance, these parasites may present a zoonotic risk either directly, or as potential vectors for bacterial pathogens. These factors necessitate efficacious and effective antiparasitic treatment programs for community dogs.
A cluster-randomised trial was performed on three islands in the Torres Strait to examine the short-term efficacy and medium-term effectiveness of three treatment programs. Treatments administered included oral oxibendazole/praziquantel (Paragard) and oral afoxolaner (Nexgard); topical moxidectin/imidacloprid (Advocate) and imidacloprid/flumethrin collars (Seresto); and off-label oral ivermectin (Bomectin). Canine faecal samples were collected and examined for endoparasites by faecal flotation and real-time PCR at baseline, 7-11 days after treatment and 6 months later.
The proportion of dogs positive for at baseline and negative at day 7-11 was 9% (95% CI 4.4-17.4) for dogs treated with oxibendazole, 56.4% (95% CI 41-70.7) for moxidectin, and 89.7% (95% CI 73.6-96.4) for ivermectin. Faecal flotation results showed a greater than 90% egg reduction in 29.2% (95% CI 19.9-40.5) of dogs treated with oxibendazole, 79.4% (95% CI 63.2-89.7) for moxidectin, and 95% (95% CI 76.4-99.1) for off-label ivermectin. Elimination of ectoparasite infestation was observed at day 7-11 in 69.9% (95% CI 56.7-80.1) of dogs treated with afoxolaner, 80% (95% CI 60.9-91.1) with imidacloprid/flumethrin collars, and 0% (95% CI 0-11.7) for off-label ivermectin. Mixed effects modelling revealed only treatment group to be significantly associated with outcome measures.
Based on these study results, the poor efficacy of oxibendazole against renders it inept for treatment, while ivermectin and moxidectin were suitable. Ivermectin was unsuitable for ectoparasite treatment due to its poor efficacy, while afoxolaner and imidacloprid/flumethrin collars appear suitable.
澳大利亚北部偏远的原住民和托雷斯海峡岛民社区的热带气候有利于犬类蠕虫(如钩虫)以及外寄生虫(如跳蚤和蜱虫)的传播。除了其兽医重要性外,这些寄生虫可能直接构成人畜共患病风险,或作为细菌病原体的潜在载体。这些因素使得有必要为社区犬实施有效且高效的抗寄生虫治疗方案。
在托雷斯海峡的三个岛屿上进行了一项整群随机试验,以检验三种治疗方案的短期疗效和中期效果。所给予的治疗包括口服奥昔苯达唑/吡喹酮(Paragard)和口服阿福拉纳(Nexgard);外用莫西菌素/吡虫啉(Advocate)和吡虫啉/氟氯氰菊酯项圈(Seresto);以及标签外口服伊维菌素(Bomectin)。在基线、治疗后7 - 11天和6个月时收集犬类粪便样本,通过粪便浮选和实时PCR检测体内寄生虫。
基线时呈阳性且在第7 - 11天呈阴性的犬只比例,接受奥昔苯达唑治疗的为9%(95%置信区间4.4 - 17.4),接受莫西菌素治疗的为56.4%(95%置信区间41 - 70.7),接受伊维菌素治疗的为89.7%(95%置信区间73.6 - 96.4)。粪便浮选结果显示,接受奥昔苯达唑治疗的犬中有29.2%(95%置信区间19.9 - 40.5)的虫卵减少率大于90%,接受莫西菌素治疗的为79.4%(95%置信区间63.2 - 89.7),接受标签外伊维菌素治疗的为95%(95%置信区间76.4 - 99.1)。在第7 - 11天,接受阿福拉纳治疗的犬中有69.9%(95%置信区间56.7 - 80.1)的外寄生虫感染被消除,接受吡虫啉/氟氯氰菊酯项圈治疗的为80%(95%置信区间60.9 - 91.1),接受标签外伊维菌素治疗的为0%(95%置信区间0 - 11.7)。混合效应模型显示只有治疗组与结果指标显著相关。
基于这些研究结果,奥昔苯达唑对[此处原文可能缺失寄生虫名称]的疗效不佳,使其不适合用于治疗,而伊维菌素和莫西菌素似乎是合适的。伊维菌素由于其对外寄生虫治疗效果不佳而不适用,而阿福拉纳和吡虫啉/氟氯氰菊酯项圈似乎是合适的。